Search Prime Grants

U01DA053043

Cooperative Agreement

Overview

Grant Description
Meth-od: A phase 2a study of IXT-M200 in methamphetamine overdose patients.
Awardee
Intervexion Therapeutics
Funding Goals
TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
93.279 - Drug Abuse and Addiction Research Programs
Awarding / Funding Agency
National Institute on Drug Abuse (NIDA) [HHS - NIH]
Place of Performance
Arkansas United States
Geographic Scope
State-Wide
Related Opportunity
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) (PAR-19-327)
Analysis Notes
Amendment Since initial award the End Date has been extended from 06/30/23 to 06/30/24 and the total obligations have increased 218% from $2,492,018 to $7,913,185.
Intervexion Therapeutics was awarded Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS Cooperative Agreement U01DA053043 worth $7,913,185 from National Institute on Drug Abuse in September 2020 with work to be completed primarily in Arkansas United States. The grant has a duration of 3 years 9 months and was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs. The Cooperative Agreement was awarded through grant opportunity Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional).

Status
(Complete)

Last Modified 11/20/24

Period of Performance
9/30/20
Start Date
6/30/24
End Date
100% Complete

Funding Split
$7.9M
Federal Obligation
$0.0
Non-Federal Obligation
$7.9M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to U01DA053043

Subgrant Awards

Disclosed subgrants for U01DA053043

Transaction History

Modifications to U01DA053043

Additional Detail

Award ID FAIN
U01DA053043
SAI Number
U01DA053043-1106610043
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Small Business
Awarding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Funding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Awardee UEI
MS3QH9KM4EN5
Awardee CAGE
4GRM3
Performance District
AR-90
Senators
John Boozman
Tom Cotton

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) Health research and training Grants, subsidies, and contributions (41.0) $4,355,120 100%
Modified: 11/20/24